These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35848643)

  • 1. Chemotherapy-Associated nausea and vomiting: A cross-sectional survey of occurrence and management patterns at jos university teaching hospital, Nigeria.
    Manyega KM; Joseph BN; Rotkangmwa OC; Dapar MP
    Ann Afr Med; 2022; 21(2):124-131. PubMed ID: 35848643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran.
    Nikbakht Z; Rajabi M; Shahrasbi A; Roohi E; Hashemian F
    J Cancer Educ; 2021 Oct; 36(5):1022-1029. PubMed ID: 31955393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
    Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
    BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of patient quality care in Spain in prevention of nausea and vomiting induced by chemotherapy.
    Escobar-Álvarez Y; de Castro-Carpeño J; Feyjoo M; Martín-Algarra S
    J Healthc Qual Res; 2021; 36(3):142-149. PubMed ID: 33744239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
    Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
    Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prophylaxis of chemotherapy-induced vomiting and nausea].
    Tóth J; Szántó J
    Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
    Berry WR; House KW; Lee JT; Plagge PB; Meshad MW; Grapski R
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):33-7. PubMed ID: 1485180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
    Holdsworth MT; Raisch DW; Winter SS; Chavez CM
    Support Care Cancer; 1998 Mar; 6(2):132-8. PubMed ID: 9540172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy.
    Jain S; Kapoor G; Koneru S; Vishwakarma G
    Support Care Cancer; 2018 Sep; 26(9):3091-3097. PubMed ID: 29564625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
    Kovács G; Wachtel AE; Basharova EV; Spinelli T; Nicolas P; Kabickova E
    Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survey ranking of emetogenic control in children receiving chemotherapy.
    Small BE; Holdsworth MT; Raisch DW; Winter SS
    J Pediatr Hematol Oncol; 2000; 22(2):125-32. PubMed ID: 10779025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.
    Navari RM; Ruddy KJ; LeBlanc TW; Nipp R; Clark-Snow R; Schwartzberg L; Binder G; Bailey WL; Potluri R; Schmerold LM; Papademetriou E; Roeland EJ
    Oncologist; 2021 Apr; 26(4):325-331. PubMed ID: 33289268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines.
    Yu S; Burke TA; Chan A; Kim HK; Hsieh RK; Hu X; Liang JT; Baños A; Spiteri C; Keefe DM
    Support Care Cancer; 2015 Jan; 23(1):273-82. PubMed ID: 25115892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.
    Stewart DJ; Dahrouge S; Coyle D; Evans WK
    J Clin Oncol; 1999 Jan; 17(1):344-51. PubMed ID: 10458253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
    Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
    Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
    Italian Group for Antiemetic Research
    N Engl J Med; 2000 May; 342(21):1554-9. PubMed ID: 10824073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.